全文获取类型
收费全文 | 2713篇 |
免费 | 159篇 |
国内免费 | 24篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 97篇 |
妇产科学 | 68篇 |
基础医学 | 402篇 |
口腔科学 | 90篇 |
临床医学 | 205篇 |
内科学 | 554篇 |
皮肤病学 | 50篇 |
神经病学 | 190篇 |
特种医学 | 193篇 |
外科学 | 451篇 |
综合类 | 43篇 |
预防医学 | 70篇 |
眼科学 | 63篇 |
药学 | 149篇 |
中国医学 | 1篇 |
肿瘤学 | 263篇 |
出版年
2023年 | 12篇 |
2022年 | 15篇 |
2021年 | 40篇 |
2020年 | 36篇 |
2019年 | 55篇 |
2018年 | 61篇 |
2017年 | 36篇 |
2016年 | 44篇 |
2015年 | 51篇 |
2014年 | 83篇 |
2013年 | 123篇 |
2012年 | 137篇 |
2011年 | 180篇 |
2010年 | 92篇 |
2009年 | 113篇 |
2008年 | 147篇 |
2007年 | 160篇 |
2006年 | 157篇 |
2005年 | 119篇 |
2004年 | 130篇 |
2003年 | 107篇 |
2002年 | 117篇 |
2001年 | 105篇 |
2000年 | 65篇 |
1999年 | 76篇 |
1998年 | 49篇 |
1997年 | 36篇 |
1996年 | 37篇 |
1995年 | 36篇 |
1994年 | 35篇 |
1993年 | 33篇 |
1992年 | 40篇 |
1991年 | 24篇 |
1990年 | 48篇 |
1989年 | 44篇 |
1988年 | 27篇 |
1987年 | 28篇 |
1986年 | 26篇 |
1985年 | 26篇 |
1984年 | 17篇 |
1983年 | 12篇 |
1982年 | 9篇 |
1981年 | 12篇 |
1980年 | 18篇 |
1979年 | 7篇 |
1978年 | 8篇 |
1977年 | 9篇 |
1976年 | 9篇 |
1974年 | 7篇 |
1970年 | 7篇 |
排序方式: 共有2896条查询结果,搜索用时 31 毫秒
1.
2.
Mark DP Willcox 《Clinical & experimental optometry》2019,102(4):350-363
This article summarises research undertaken since 1993 in the Willcox laboratory at the University of New South Wales, Sydney on the tear film, its interactions with contact lenses, and the use of tears as a source of biomarkers for ocular and non‐ocular diseases. The proteome, lipidome and glycome of tears all contribute to important aspects of the tear film, including its structure, its ability to defend the ocular surface against microbes and to help heal ocular surface injuries. The tear film interacts with contact lenses in vivo and interactions between tears and lenses can affect the biocompatibility of lenses, and may be important in mediating discomfort responses during lens wear. Suggestions are made for follow‐up research. 相似文献
3.
Petros Petrikis Stelios Tigas Alexandros T. Tzallas Andreas Karampas Ioannis Papadopoulos Petros Skapinakis 《International journal of psychiatry in clinical practice》2020,24(1):20-24
AbstractAim: Sex differences have long been reported in schizophrenia leading to the hypothesis that sex hormones may be implicated in the pathophysiology of the disorder. We assessed gonadal hormones during the fasted state in drug-naïve patients with psychosis.Method: Fasting serum concentrations of follicular-stimulating hormone (FSH) and luteinizing hormone (LH), testosterone, free-testosterone, Sex Hormone Binding Globulin (SHBG) and oestradiol (E2) were compared between a group of 55 newly diagnosed, drug-naïve, first-episode men with psychosis and a group of 55 healthy controls, matched for age, smoking status and BMI. Testosterone, free-testosterone and SHBG were compared between a group of 32 drug-naïve, first-episode females with psychosis and a group of 32 healthy controls matched for age, smoking status and BMI.Results: Testosterone and free-testosterone levels were significantly lower in the patients’ group and SHBG levels significantly higher in the patients’ group compared to those in healthy controls. The two female groups had similar values in the hormones which were measured.Conclusion: Our findings provide evidence of lower testosterone and free-testosterone levels and increased SHBG levels in drug-naïve, first-episode males with psychosis.
- KEY POINTS
Reduced testosterone and free-testosterone levels in drug-naive, first-episode males with psychosis.
Increased SHBG levels in drug-naive first-episode males with psychosis.
No difference in FSH, LH and E2 levels between drug-naive first episode males with psychosis and controls.
No difference in testosterone, free-testosterone and SHBG levels between drug-naive, first-episode women with psychosis and controls.
4.
5.
Nikolaos G. Papadopoulos Adnan ustovi Michael D. Cabana Sharon D. Dell Antoine Deschildre Gunilla Hedlin Elham Hossny Peter Le Souëf Paolo M. Matricardi Antonio Nieto Wanda Phipatanakul Paulo M. Pitrez Petr Pohunek Marcela Gavornikova Xavier Jaumont David B. Price 《Pediatric allergy and immunology》2019,30(1):7-16
6.
Frontera Jennifer A. Bhatt Prachi Lalchan Rebecca Yaghi Shadi Ahuja Tania Papadopoulos John Joset Danielle 《Journal of thrombosis and thrombolysis》2020,49(1):121-131
Journal of Thrombosis and Thrombolysis - Andexanet-alpha is a specific reversal agent for direct factor Xa inhibitors (dFXaI). We aimed to project utilization rates and cost of andexanet for... 相似文献
7.
Marek Ruszczyński Dominika Ambrożej Aleksander Adamiec Klaudia Ryczaj Varpu Elenius Ozlem Cavkaytar Paraskevi Maggina Heidi Makrinioti Nikolaos Papadopoulos Gunilla Hedlin Jon R. Konradsen Bianca Schaub Hermelijn H. Smits Tuomas Jartti Wojciech Feleszko EAACI Task Force on Clinical Practice Recommendations on Preschool Wheeze 《Pediatric allergy and immunology》2021,32(1):92-105
8.
Yu Lin Wang Marco R. Scipione Yanina Dubrovskaya John Papadopoulos 《Antimicrobial agents and chemotherapy》2014,58(1):176-182
The treatment of choice for Stenotrophomonas maltophilia is trimethoprim-sulfamethoxazole (SXT). Fluoroquinolones (FQs) have in vitro activity against S. maltophilia; however, there is limited published information on their effectiveness. The purpose of this study is to compare the effectiveness of FQs and SXT for the treatment of S. maltophilia. A retrospective review of 98 patients with S. maltophilia infections who received SXT or FQ monotherapy was conducted. Patients ≥18 years old with a positive culture for S. maltophilia and clinical signs of infection who received treatment for ≥48 h were included. Microbiological cure and clinical response were evaluated at the end of therapy (EOT). In-hospital mortality and isolation of nonsusceptible isolates were also evaluated. Thirty-five patients received SXT, and 63 patients received FQ; 48 patients received levofloxacin, and 15 patients received ciprofloxacin. The most common infection was pulmonary. The overall microbiological cure rate at EOT was 63%. Thirteen of 20 patients (65%) who received SXT and 23 of 37 patients (62%) who received FQ had microbiological cure at EOT (P = 0.832). The overall clinical success rate was 55%, 52% for those who received FQ and 61% for those who received SXT (P = 0.451). In-hospital mortality was 24%, with similar rates in the two groups (25% for FQ versus 22% for SXT; P = 0.546). Development of resistance on repeat culture was 30% for FQ and 20% for SXT (P = 0.426). Fluoroquinolone and SXT monotherapies may be equally effective for the treatment of S. maltophilia infections. Resistance was documented in subsequent isolates of S. maltophilia in both groups. 相似文献
9.
10.
David M. Fleischer Scott Sicherer Matthew Greenhawt Dianne Campbell Edmond Chan Antonella Muraro Susanne Halken Yitzhak Katz Motohiro Ebisawa Lawrence Eichenfield Hugh Sampson Gideon Lack George Du Toit Graham Roberts Henry Bahnson Mary Feeney Jonathan Hourihane Jonathan Spergel Michael Young Amal As'aad Katrina Allen Susan Prescott Sandeep Kapur Hirohisa Saito Ioana Agache Cezmi A. Akdis Hasan Arshad Kirsten Beyer Anthony Dubois Philippe Eigenmann Monserrat Fernandez‐Rivas Kate Grimshaw Karin Hoffman‐Sommergruber Arne Host Susanne Lau Liam O'Mahony Clare Mills Nikolaus Papadopoulos Carina Venter Nancy Agmon‐Levin Aaron Kessel Richard Antaya Beth Drolet Lanny Rosenwasser 《Pediatric dermatology》2016,33(1):103-106
The purpose of this brief communication is to highlight emerging evidence regarding potential benefits of supporting early rather than delayed peanut introduction during the period of complementary food introduction in infants. This document should be considered as interim guidance based on consensus among the following organizations: American Academy of Allergy, Asthma, and Immunology, American Academy of Pediatrics, American College of Allergy, Asthma, and Immunology, Australasian Society of Clinical Immunology and Allergy, Canadian Society of Allergy and Clinical Immunology, European Academy of Allergy and Clinical Immunology, Israel Association of Allergy and Clinical Immunology, Japanese Society for Allergology, Society for Pediatric Dermatology, and World Allergy Organization. More formal guidelines regarding early‐life, complementary feeding practices and the risk of allergy development will follow in the next year from the National Institute of Allergy and Infectious Diseases—sponsored Working Group and the European Academy of Allergy and Clinical Immunology. 相似文献